Immortality by 2039

“Immortality by 2039” is bryan johnson’s stated aspirational target for blueprint and dont die. In a 2026-01-30 Blueprint article, he says: “by 2039, my goal is immortality,” while explicitly acknowledging he may fail. He operationalizes success as one year of chronological time passing while biological age stays the same.

Argument structure

Johnson’s argument has four parts:

  1. Biology has examples of extreme longevity / agelessness: he invokes hydra, Turritopsis dohrnii, and lobster telomerase as motifs that nature has solved pieces of the problem.
  2. Aging is an engineering problem: immortality is framed as biological engineering, not a physics impossibility.
  3. AI accelerates discovery: AI moving from assistant to scientist plus richer biomarker measurement could create a closed-loop improvement system.
  4. Blueprint is the personal prototype: six years of measurement, interventions, and iteration allegedly produced elite-young adult levels in several systems, while revealing remaining deficits.

Implementation direction

The article says Johnson is having thousands of organ clones built in dishes to test drugs and molecules against his own biology. The goal is to accelerate learning while reducing direct bodily risk.

Philosophical / AI dimension

Johnson says the 2039 goal is not only about living forever; it is a way to focus collective attention on a positive goal and move society from YOLO to dont die. He frames this as part of surviving superintelligence: if AI changes everything, society needs a stabilizing aspiration around existence.

On X, he often repeats adjacent formulations: humans may be “the first generation to not die,” lifespans may become so long that people stop thinking about lifespans, and Blueprint is becoming infrastructure for people who want to “play the immortality by 2039 game.”

Why confidence is low

This page marks confidence low because the timeline is speculative. The source set supports that Johnson publicly holds and promotes the goal, but not that immortality by 2039 is scientifically likely. Key missing evidence:

  • independent geroscience forecasts;
  • clinical feasibility of organ-clone drug screening as a generalized anti-aging accelerator;
  • safety/efficacy data for therapies that reverse whole-body biological age without unacceptable cancer or other risks;
  • definitions distinguishing actuarial immortality, longevity escape velocity, negligible senescence, and “not thinking about lifespans.”